After successful launch, confirms additional $4.2 Million Purchase Order
VANCOUVER, BC, Dec. 2, 2021 /CNW/ – Atmofizer Technologies Inc. (the “Company” or “Atmofizer“) (CSE: ATMO) (Frankfurt: J3K) is pleased to announce that the Company has entered into a non-exclusive distribution agreement with USA Rapid Test, LLC (“USA Rapid Test“) under which USA Rapid Test has placed an initial purchase order for US$4.2 million personal space, Atmofizer A500s.
USA Rapid Test, based out of Clearwater, Florida, is an industry-leading distributor of COVID-19 rapid tests and distributes to major companies in the healthcare, retail, hospitality, education and entertainment industries. In accordance with terms of the distribution agreement, USA Rapid Test will hold non-exclusive rights to distribute Atmofizer products throughout the United States through online, B2C and B2B channels.
“There is no comparison to the level of clean air the Atmofizer produces and selling it as simple as walking into a room that has one,” said USA Rapid Test COO, Monica Agami. “The technology is revolutionary and the difference in the air’s breathability is remarkable. We can now create safer ‘bubbles’ in not just doctor’s offices or hotel rooms but also homes, businesses, classrooms, or locker rooms.”
“We’re excited to have USA Rapid Test as a partner. The scale of their first order is a testament to their commitment, the momentum in the space and the size of the market. The air we breathe is at the center of the…
